People

Inhaled antiviral developer Pneumagen has announced the appointment of Adaptimmune Therapeutics founder James Noble as non-executive Chairman of the company’s board of directors. Noble also co-founded Immunocore and serves as Chairman of Sutura Therapeutics, Celleron,… Read more . . .

Copley Scientific has announced the appointments of Jamie Clayton as Managing Director and Matthew Fenn as Head of Business Development. Clayton joined powder characterization specialist Freeman Technology in 2008 and then served as Freeman’s Operations… Read more . . .

Aerami Therapeutics has announced that its current Chief Operating Officer Lisa Yañez will succeed Steve Thornton as CEO, effective January 1, 2023. Thornton will continue as a member of the Board of Directors. Prior to… Read more . . .

TFF Pharmaceuticals, which develops dry powder inhalation products based on its thin film freezing technology, has announced that Glenn Mattes will step down as CEO and that he will be succeeded on an interim basis… Read more . . .

InvisiShield Technologies, which is developing a human antibody nasal spray designed to prevent SARS-CoV-2 infection, has announced the appointment of Gladstone Institute of Virology and Immunology founding director Warner C. Greene as President and Chief… Read more . . .

OBG subsidiary Noveayr Therapeutics has announced the appointments of former AstraZeneca VP, Respiratory, Simon Manners as CEO and former GSK Senior VP, Respiratory, Darrell Baker as Chairman. Noveayr is the parent company of Pharmaserve NW,… Read more . . .

Avalyn Pharma, which is developing its AP01 pirfenidone inhalation solution for the treatment of idiopathic pulmonary fibrosis (IPF), has named Lyn Baranowski as CEO, succeeding Bruce Montgomery. Baranowski was most recently Chief Operating Officer of… Read more . . .

Transpire Bio, a start-up inhaled drug developer based in Florida, has announced the appointment of two more OINDP experts, naming William Schachtner as Chief Technical Operations Officer and Axel Perlwitz as Chief Regulatory Affairs Officer.… Read more . . .

Inhaled flecanide developer InCarda Therapeutics has named former Arena Pharmaceuticals executive Robert Lisicki as CEO, succeeding Grace Colón who the company says “intends to pursue other leadership opportunities within the life science space” but will continue… Read more . . .